Spis treści:
Spis załączników:
SFA_2025_Capital_Increase_Results_EN_espi.pdf (REPORT)
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
SFA_2025_Capital_Increase_Results_EN_espi.pdf (REPORT)
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 3 | / | 2025 | ||||||||
| Date of issue: | 2025-01-15 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212 | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that in pursuance of a decision of the Board of Directors of SOPHARMA AD from October 14, 2024 and based on art. 195 and art. 196 of the Commercial Law (CL), art. 113, para. 2, item 2 of Law on public offering of securities (LPOS) and art. 25 of the Articles of incorporation of the company a procedure for capital increase was launched for issuing up to 623 779 ordinary registered dematerialized freely transferable shares with a nominal value of BGN 1 each and issue value of BGN 4.13 for one share, under the condition that the shares of the increase are subscribed by the holders of warrants of issue with ISIN BG9200001212, in accordance with the terms and conditions described in the Prospectus for Public Offering of Warrants, confirmed by a Decision of the Financial Supervision Commission (FSC) No 804-E/ 04.11.2021. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_2025_Capital_Increase_Results_EN_espi.pdfSFA_2025_Capital_Increase_Results_EN_espi.pdf | Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) |
||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2025-01-15 | Ognian Donev | Executive director | |||